AR030277A1 - Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla - Google Patents

Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla

Info

Publication number
AR030277A1
AR030277A1 ARP010101663A ARP010101663A AR030277A1 AR 030277 A1 AR030277 A1 AR 030277A1 AR P010101663 A ARP010101663 A AR P010101663A AR P010101663 A ARP010101663 A AR P010101663A AR 030277 A1 AR030277 A1 AR 030277A1
Authority
AR
Argentina
Prior art keywords
heterocyclic
keto
oxo
aryl
hydroxy
Prior art date
Application number
ARP010101663A
Other languages
English (en)
Spanish (es)
Inventor
Makoto Suematsu
Ryuji Ueno
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR030277A1 publication Critical patent/AR030277A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP010101663A 2000-04-06 2001-04-06 Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla AR030277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19489400P 2000-04-06 2000-04-06

Publications (1)

Publication Number Publication Date
AR030277A1 true AR030277A1 (es) 2003-08-20

Family

ID=22719290

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101663A AR030277A1 (es) 2000-04-06 2001-04-06 Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla

Country Status (15)

Country Link
US (2) US6469062B2 (enExample)
EP (1) EP1267883B1 (enExample)
JP (2) JP4183943B2 (enExample)
KR (1) KR100874626B1 (enExample)
CN (1) CN1241570C (enExample)
AR (1) AR030277A1 (enExample)
AT (1) ATE433754T1 (enExample)
AU (2) AU4472701A (enExample)
BR (1) BR0107544A (enExample)
CA (1) CA2404767C (enExample)
DE (1) DE60139002D1 (enExample)
MX (1) MXPA02009915A (enExample)
NZ (1) NZ521784A (enExample)
TW (1) TWI232750B (enExample)
WO (1) WO2001076593A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4183943B2 (ja) * 2000-04-06 2008-11-19 スキャンポ・アーゲー 15−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
AU2007223469B2 (en) * 2006-02-28 2012-06-07 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
KR102595299B1 (ko) 2020-10-12 2023-10-26 류형준 담즙 분비 촉진 효능이 있는 식품 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58203911A (ja) * 1982-05-25 1983-11-28 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する細肪障害治療剤
JPS6327433A (ja) 1986-07-21 1988-02-05 Teijin Ltd 肝疾患治療剤
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5076569A (en) * 1989-09-15 1991-12-31 Gootter Steven M Contoured grip for exercising the hand
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JPH069404A (ja) 1992-06-23 1994-01-18 Ono Pharmaceut Co Ltd 臓器移植用薬剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
JP4183943B2 (ja) * 2000-04-06 2008-11-19 スキャンポ・アーゲー 15−ケトプロスタグランジンを含む胆汁分泌促進剤組成物

Also Published As

Publication number Publication date
EP1267883A2 (en) 2003-01-02
CA2404767A1 (en) 2001-10-18
EP1267883B1 (en) 2009-06-17
KR20020087123A (ko) 2002-11-21
BR0107544A (pt) 2005-01-11
MXPA02009915A (es) 2003-03-27
US20030060506A1 (en) 2003-03-27
CA2404767C (en) 2010-12-07
US20020004524A1 (en) 2002-01-10
WO2001076593A3 (en) 2002-07-11
JP2004519412A (ja) 2004-07-02
DE60139002D1 (de) 2009-07-30
US6469062B2 (en) 2002-10-22
KR100874626B1 (ko) 2008-12-17
AU2001244727B2 (en) 2006-08-10
JP4183943B2 (ja) 2008-11-19
ATE433754T1 (de) 2009-07-15
AU4472701A (en) 2001-10-23
JP5073588B2 (ja) 2012-11-14
CN1241570C (zh) 2006-02-15
JP2008291033A (ja) 2008-12-04
CN1450899A (zh) 2003-10-22
NZ521784A (en) 2005-04-29
WO2001076593A2 (en) 2001-10-18
TWI232750B (en) 2005-05-21

Similar Documents

Publication Publication Date Title
AR030277A1 (es) Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
ATE489101T1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
TW200607451A (en) Azinylimidazoazines and azinylcarboxamides
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
DE60120151D1 (de) Isolierung von mesenchymalen stammzellen und deren verwendung
AR110149A2 (es) Composición catártica
PE20050194A1 (es) Derivados de piridina-2-carboxamida como activadores de glucoquinasa
AR073158A1 (es) Metodo y composicion para modular el crecimiento de celulas madre
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
AR035237A1 (es) Uso de un compuesto 15-cet-prostaglandina para fabricar una composicion para tratar estrenimiento inducido por drogas
WO2005030120A3 (en) Antiangiogenic agents
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
CO5271666A1 (es) Derivados de pirimidina
DK1490492T3 (da) Hybridt hepatocytvækstfaktorgen med höj ekspressionseffektivitet af to heterotyper af hepatocytvækstfaktor
DK1765816T3 (da) Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande
DE60318826D1 (de) Alkoxypyridinderivate
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
SV2006002069A (es) Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación
DK1165113T3 (da) Anvendelse af ErbB-receptorligander i behandling af diabetes

Legal Events

Date Code Title Description
FC Refusal